Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of Cortagen and Vesugen — mechanism, side effects, legal status, and pricing.
A short synthetic peptide bioregulator (Ala-Glu-Asp-Pro) from the Khavinson 'Cytomax/Cytogen' family, marketed for cartilage and connective-tissue support. Evidence is largely Russian-language and preclinical.
Vesugen is a synthetic tripeptide, Lys-Glu-Asp (KED), from the Khavinson short-peptide 'bioregulator' series, positioned as a short-peptide analog of a bovine vascular-tissue polypeptide complex and claimed to be vasoprotective. Marketed on the Russian/Ukrainian grey market; not FDA-approved in the US; research-use only.
Cortagen
Vesugen
Category
Legal Status
Mechanism
Side Effects
Contraindications
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
Cortagen
Vesugen
COA corpus from Disclosed Labs — independently tested batches only.
Cortagen
9
COAs
99.6%
Avg purity
4
Labs
Vesugen
10
COAs
99.6%
Avg purity
5
Labs
Primarily Russian institutional studies; no large independent controlled human trials.
Evidence base is single-lab (Khavinson/Linkova and collaborators). Preclinical work includes organotypic neuroimmunoendocrine cultures (Bull Exp Biol Med 2012) and endothelial-cell epigenetics studies (Adv Gerontol 2014). No FDA-registered trials; no Western RCTs in vascular disease.
Key references
Cortagen and Vesugen are both in the Recovery category and may have overlapping mechanisms. Researchers should review both profiles carefully, understand the mechanisms of action, and monitor the relevant biomarkers when combining compounds in the same class. As always, consult a licensed healthcare provider before making any decisions about combining research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Lab Testing